Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fluoxetine + DHEA
- Development stage
- Phase 1
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination of fluoxetine, a selective serotonin reuptake inhibitor (SSRI) antidepressant, and DHEA (dehydroepiandrosterone), a naturally occurring hormone that can be manufactured as a dietary supplement. This combination has shown synergistic effects in increasing progenitor cell proliferation in the adult hippocampus at lower doses of fluoxetine than would be effective alone, which may contribute to its antidepressant properties. The combination has also been studied for its effects on hypoglycemia responses in individuals with Type 1 diabetes and for treating canine aggression.
02
Targets
SERT (Sodium-dependent serotonin transporter)
Beyond the preview
Go deeper on fluoxetine + DHEA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fluoxetine + DHEA.